🇺🇸 FDA
Patent

US 7196184

Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene

granted A61KA61K38/00A61P

Quick answer

US patent 7196184 (Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene) held by Alnylam Europe AG expires Mon Mar 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Europe AG
Grant date
Tue Mar 27 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K38/00, A61P, A61P35/00